trump and glp 1 meds officials plan coverage for weight loss drugs under Medicare Medicaid | Trump administration Pres. Donald Trump announced that
Description
Nakajima K, Nagamine T, Fujita MQ, Ai M, Tanaka A, Schaefer E
SAR441255, a recently developed triple-agonist based on the exendin-4 sequence, demonstrates improved glycemic control in healthy human subjects following a mixed meal test in a phase Ia single dose clinical trial
Cutting coverage for modern medicine could make these health gaps even wider
It has also been shown to be involved in metabolic mechanisms like metabolism and GLP-1 stimulation and could help to manage weight in overweight individuals
